Generation Bio Co. (NASDAQ:GBIO) Short Interest Down 13.4% in October

Generation Bio Co. (NASDAQ:GBIO - Get Free Report) was the recipient of a significant decrease in short interest in October. As of October 15th, there was short interest totalling 1,740,000 shares, a decrease of 13.4% from the September 30th total of 2,010,000 shares. Based on an average daily volume of 101,500 shares, the short-interest ratio is currently 17.1 days. Approximately 3.6% of the company's stock are sold short.

Generation Bio Stock Up 2.1 %

GBIO stock traded up $0.05 during mid-day trading on Tuesday, reaching $2.39. 97,275 shares of the stock traded hands, compared to its average volume of 181,720. The firm has a market capitalization of $159.51 million, a PE ratio of -1.00 and a beta of 2.80. The business has a 50-day moving average of $2.46 and a two-hundred day moving average of $2.77. Generation Bio has a 52 week low of $0.89 and a 52 week high of $4.65.

Generation Bio (NASDAQ:GBIO - Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.04). The firm had revenue of $4.09 million for the quarter, compared to analyst estimates of $3.23 million. Generation Bio had a negative return on equity of 92.86% and a negative net margin of 1,202.56%. On average, equities research analysts anticipate that Generation Bio will post -1.8 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on GBIO. Needham & Company LLC reissued a "buy" rating and issued a $10.00 price objective on shares of Generation Bio in a research note on Wednesday, October 23rd. Wedbush reiterated an "outperform" rating and set a $5.00 price target on shares of Generation Bio in a report on Thursday, August 8th.

Hedge Funds Weigh In On Generation Bio

Several institutional investors have recently bought and sold shares of the business. PFG Advisors bought a new stake in Generation Bio in the first quarter valued at approximately $41,000. SG Americas Securities LLC acquired a new position in Generation Bio in the third quarter valued at about $42,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Generation Bio in the first quarter worth about $74,000. Cubist Systematic Strategies LLC raised its position in shares of Generation Bio by 91.0% during the second quarter. Cubist Systematic Strategies LLC now owns 19,046 shares of the company's stock worth $54,000 after purchasing an additional 9,075 shares during the period. Finally, American Century Companies Inc. lifted its holdings in shares of Generation Bio by 199.3% during the 2nd quarter. American Century Companies Inc. now owns 31,786 shares of the company's stock valued at $90,000 after purchasing an additional 21,167 shares in the last quarter. Institutional investors own 95.22% of the company's stock.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.